Medtronic (MDT) Competitors $89.53 0.00 (0.00%) As of 12:57 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock MDT vs. DXCM, ISRG, ABT, JNJ, NVST, SYK, TMO, BSX, BDX, and EWShould you be buying Medtronic stock or one of its competitors? The main competitors of Medtronic include DexCom (DXCM), Intuitive Surgical (ISRG), Abbott Laboratories (ABT), Johnson & Johnson (JNJ), Envista (NVST), Stryker (SYK), Thermo Fisher Scientific (TMO), Boston Scientific (BSX), Becton, Dickinson and Company (BDX), and Edwards Lifesciences (EW). These companies are all part of the "medical" sector. Medtronic vs. Its Competitors DexCom Intuitive Surgical Abbott Laboratories Johnson & Johnson Envista Stryker Thermo Fisher Scientific Boston Scientific Becton, Dickinson and Company Edwards Lifesciences DexCom (NASDAQ:DXCM) and Medtronic (NYSE:MDT) are both large-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, risk, valuation, dividends, media sentiment, profitability, earnings and institutional ownership. Which has stronger earnings & valuation, DXCM or MDT? Medtronic has higher revenue and earnings than DexCom. Medtronic is trading at a lower price-to-earnings ratio than DexCom, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioDexCom$4.03B8.19$576.20M$1.3462.87Medtronic$33.54B3.43$4.66B$3.6224.80 Is DXCM or MDT more profitable? Medtronic has a net margin of 13.90% compared to DexCom's net margin of 12.90%. DexCom's return on equity of 30.05% beat Medtronic's return on equity.Company Net Margins Return on Equity Return on Assets DexCom12.90% 30.05% 10.00% Medtronic 13.90%14.54%7.83% Do analysts recommend DXCM or MDT? DexCom presently has a consensus price target of $99.60, indicating a potential upside of 18.23%. Medtronic has a consensus price target of $98.19, indicating a potential upside of 9.35%. Given DexCom's stronger consensus rating and higher possible upside, research analysts clearly believe DexCom is more favorable than Medtronic.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score DexCom 0 Sell rating(s) 4 Hold rating(s) 16 Buy rating(s) 2 Strong Buy rating(s) 2.91Medtronic 0 Sell rating(s) 11 Hold rating(s) 9 Buy rating(s) 2 Strong Buy rating(s) 2.59 Which has more risk & volatility, DXCM or MDT? DexCom has a beta of 1.44, indicating that its stock price is 44% more volatile than the S&P 500. Comparatively, Medtronic has a beta of 0.8, indicating that its stock price is 20% less volatile than the S&P 500. Does the media prefer DXCM or MDT? In the previous week, Medtronic had 37 more articles in the media than DexCom. MarketBeat recorded 54 mentions for Medtronic and 17 mentions for DexCom. DexCom's average media sentiment score of 1.36 beat Medtronic's score of 1.20 indicating that DexCom is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment DexCom 12 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Medtronic 44 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Do institutionals & insiders have more ownership in DXCM or MDT? 97.8% of DexCom shares are held by institutional investors. Comparatively, 82.1% of Medtronic shares are held by institutional investors. 0.3% of DexCom shares are held by insiders. Comparatively, 0.2% of Medtronic shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. SummaryDexCom beats Medtronic on 11 of the 16 factors compared between the two stocks. Get Medtronic News Delivered to You Automatically Sign up to receive the latest news and ratings for MDT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MDT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MDT vs. The Competition Export to ExcelMetricMedtronicMED PRODUCTS IndustryMedical SectorNYSE ExchangeMarket Cap$115.16B$10.22B$5.53B$20.78BDividend Yield3.16%2.05%3.80%3.69%P/E Ratio24.8016.6128.0327.64Price / Sales3.4329.54445.6858.49Price / Cash11.5822.2635.8422.13Price / Book2.393.618.214.66Net Income$4.66B$235.43M$3.24B$994.58M7 Day Performance-0.26%-1.03%1.75%-0.08%1 Month Performance4.80%3.55%8.20%5.21%1 Year Performance10.56%-15.99%30.66%10.63% Medtronic Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MDTMedtronic4.6479 of 5 stars$89.530.0%$98.19+9.7%+10.2%$114.86B$33.54B24.7495,000Positive NewsAnalyst ForecastAnalyst RevisionDXCMDexCom4.7948 of 5 stars$85.20+2.2%$98.50+15.6%-26.6%$33.39B$4.15B63.5410,300Positive NewsAnalyst ForecastISRGIntuitive Surgical4.7121 of 5 stars$519.40+1.4%$592.86+14.1%+21.1%$186.16B$8.35B76.1615,638Positive NewsUpcoming EarningsAnalyst RevisionABTAbbott Laboratories4.9888 of 5 stars$132.55+0.4%$143.11+8.0%+15.3%$230.62B$42.34B17.19114,000Trending NewsEarnings ReportEx-DividendAnalyst ForecastJNJJohnson & Johnson4.7879 of 5 stars$156.57-0.2%$171.00+9.2%+4.1%$376.71B$89.33B17.42138,100Trending NewsEarnings ReportDividend AnnouncementAnalyst ForecastOptions VolumeAnalyst RevisionNVSTEnvista3.537 of 5 stars$20.08-0.6%$20.23+0.7%+15.1%$3.41B$2.51B-3.0812,300News CoverageAnalyst RevisionSYKStryker4.4708 of 5 stars$392.29+0.7%$428.55+9.2%+16.3%$149.88B$22.60B53.0653,000Positive NewsTMOThermo Fisher Scientific4.9933 of 5 stars$426.69-1.9%$600.30+40.7%-23.4%$161.07B$42.90B25.03125,000Positive NewsUpcoming EarningsAnalyst ForecastAnalyst RevisionBSXBoston Scientific4.6338 of 5 stars$104.88+1.6%$116.09+10.7%+35.1%$155.16B$16.75B76.5553,000Trending NewsUpcoming EarningsBDXBecton, Dickinson and Company4.7639 of 5 stars$176.73+0.4%$219.22+24.0%-22.8%$50.65B$20.87B33.7374,000Analyst RevisionEWEdwards Lifesciences4.3879 of 5 stars$78.66+0.8%$80.40+2.2%-12.7%$46.14B$5.44B11.2415,800Positive NewsUpcoming EarningsAnalyst Forecast Related Companies and Tools Related Companies DXCM Competitors ISRG Competitors ABT Competitors JNJ Competitors NVST Competitors SYK Competitors TMO Competitors BSX Competitors BDX Competitors EW Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:MDT) was last updated on 7/18/2025 by MarketBeat.com Staff From Our PartnersYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThis Could Be the Most Profitable Season of Your LifeInstitutional money is pouring in. Bitcoin ETFs are live. Altcoin adoption is accelerating. This is the sam...Crypto Swap Profits | SponsoredNew crypto laws coming. Will you win or lose?Washington’s first-ever “Crypto Week” could trigger a major Bitcoin surge — but one trader says don’t just buy...Brownstone Research | SponsoredI warned you about Nvidia… now look what’s happeningNvidia just got Trump’s greenlight to sell high-powered AI chips to China — and their stock surged 5% before t...Timothy Sykes | Sponsored"I'm risking my reputation on this"Behind closed doors, away from the mainstream media's eyes, the smartest minds in crypto are all seeing the sa...Crypto 101 Media | SponsoredWill I be blacklisted?Porter Stansberry says a financial force bigger than 9/11 or COVID is already ripping through America — and mo...Porter & Company | Sponsored“All the land that you see I will give to you and your offspring forever…”“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Medtronic PLC Please log in to your account or sign up in order to add this asset to your watchlist. Share Medtronic With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
